Exchange: NASDAQ·Updated 04:18 PM EDT
News
all
press releases
Zoetis (ZTS) Surpasses Q2 Earnings Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +1.63% and -0.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares increasedread more...
Benzinga
Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associatedread more...
Benzinga
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -11.11% and +8.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vivos Therapeutics Inc Full Year Sales Increase
(RTTNews) - Vivos Therapeutics Inc (VVOS) released Loss for full year of -$21.17 million...
Nasdaq News: Markets
Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor stake, Quhuo Ltd. reports loss.read more...
Benzinga
Insider Buying: Vivos Therapeutics (NASDAQ:VVOS) Major Shareholder Buys 1,353,625 Shares of Stock
Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) major shareholder Michael Skaff purchased 1,353,625 shares of the business's stock in a transaction on Tuesday, March 31st. The stock was...
MarketBeat
Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours
Vivos Therapeutics shares surge 21.21% after hours as a Michigan-based investor group acquires a 19.9% stake through a $2.39 million private placement.read more...
Benzinga
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +323.53% and -84.40%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -86.47% and -23.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.